T

    Tango Therapeutics Inc (TNGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $22.84
    -0.50 (-2.14%)

    Market Cap: $3.85B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(12/21)
    Avg Surprise
    +17.85%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.33
    Range$-0.38 - $-0.26
    11 analysts
    EPS Revisions
    1
    0
    7d
    4
    1
    30d
    EPS Estimate Drift
    90d ago$-0.34-1.8%
    60d ago$-0.34-3.2%
    30d ago$-0.33-0.2%
    7d ago$-0.33+0.0%
    Current$-0.33
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.41
    Range$-0.60 - $-0.20
    13 analysts
    Revenue Consensus
    $-578090
    Range$-578090 - $-578090
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.41---
    Sep 26EST
    		-$-0.33---
    Jun 26
    Reported Aug 4
    		$-0.37$-0.31-19.35%Miss-5.7%
    Mar 26
    Reported May 13
    		$-0.32$-0.30-7.85%Miss+11.1%
    Dec 25
    Reported Mar 5
    		$-0.29$-0.33+12.12%Beat+14.7%
    Sep 25
    Reported Nov 4
    		$0.13$-0.07+285.71%Beat+148.1%
    Jun 25
    Reported Aug 5
    		$-0.35$-0.34-2.94%Miss-45.8%
    Mar 25
    Reported May 12
    		$-0.36$-0.35-2.86%Miss-2.9%
    Dec 24
    Reported Feb 27
    		$-0.34$-0.34+0.82%Beat-6.3%
    Sep 24
    Reported Nov 6
    		$-0.27$-0.37+27.03%Beat-17.4%
    Jun 24
    Reported Aug 7
    		$-0.24$-0.35+31.43%Beat-4.3%
    Mar 24
    Reported May 8
    		$-0.35$-0.31-12.90%Miss-9.4%
    Dec 23
    Reported Mar 18
    		$-0.32$-0.28-14.29%Miss+3.0%
    Sep 23
    Reported Nov 8
    		$-0.23$-0.34+32.35%Beat+30.3%
    Jun 23
    Reported Aug 7
    		$-0.23$-0.34+32.35%Beat+17.9%
    Mar 23
    Reported May 9
    		$-0.32$-0.35+8.57%Beat-10.3%
    Dec 22
    Reported Mar 27
    		$-0.33$-0.35+5.71%Beat-32.0%
    Sep 22
    Reported Nov 10
    		$-0.33$-0.32-3.13%Miss-17.9%
    Jun 22
    Reported Aug 10
    		$-0.28$-0.32+12.50%Beat-75.0%
    Mar 22
    Reported May 11
    		$-0.29$-0.27-7.41%Miss-2800.0%
    Dec 21
    Reported Mar 28
    		$-0.25$-0.27+7.41%Beat-7475.8%
    Sep 21
    Reported Nov 9
    		$-0.28$-0.28+0.00%Beat-11100.0%
    Jun 21
    Reported Jul 16
    		$-0.16$-0.14-10.34%Miss-
    Mar 21
    Reported May 14
    		$-0.01N/AN/ABeat-
    Dec 20
    Reported Mar 31
    		$-0.00N/AN/ABeat-
    Sep 20
    Reported Nov 13
    		$-0.00N/AN/ABeat-
    Jun 20
    Reported Jul 30
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-26.87EV/EBITDA-0.91x
    Price/FCF-23.72xFCF Yield-4.22%
    Profitability
    Profit Margin-229.90%Operating Margin-253.40%
    ROE-21.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage15.27x
    Current Ratio50.82xQuick Ratio50.82x
    Trading Statistics
    Beta1.15Avg Volume2.16M
    52-Week High$34.3952-Week Low$6.25

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$24.42
    SMA 20$25.73
    SMA 50$27.62
    SMA 200$19.31
    EMA 10$24.48
    EMA 20$25.33
    EMA 50$26.17
    EMA 200$20.52

    MACD

    Line: -1.03Signal: -0.88Hist: -0.15

    ADX

    ADX: 18.0+DI: 16.2-DI: 28.7

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down100.0
    PSAR$27.00

    Bollinger Bands

    Upper Band$29.42
    Lower Band$22.03
    %B Position2872%(Upper)
    Band Width0.11

    RSI (14-Day)

    Neutral
    35.1

    Momentum Oscillators

    Stoch %K20.1
    Stoch %D29.8
    Williams %R-94.8
    ROC (10d)-9.7%
    Momentum-2.45
    CCI (20d)-140.9
    MFI (14d)53.1

    Volatility Measures

    ATR (14d)$1.61(7.1%)
    StdDev (20d)1.85
    Hist Vol59.3%(High)

    Volume Flow

    VWAP$22.98
    OBV152.8M
    AD Line3.0M
    CMF (20d)-0.270

    Volume Metrics

    Avg Vol (20d)2.2M
    Vol Ratio0.9x
    VWMA (20d)$25.69

    Pivot Points

    R3$26.34
    R2$25.71
    R1$24.52
    Pivot Point$23.90
    S1$22.71
    S2$22.09
    S3$20.91

    Advanced Oscillators

    TSI-19.04
    Ultimate Osc35.4
    KST-128.76

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$53.81M$3.18M$5.39M$4.12M$11.61M$19.88M$6.47M$5.43M$10.73M
    Cost of Revenue$0$0$479,000$0$0$0$620,000$0$0$0$617,000$0
    Gross Profit$0$0$-479,000$53.81M$3.18M$5.39M$4.12M$11.61M$19.88M$6.47M$5.43M$10.73M
    Operating Expenses$59.78M$48.77M$41.86M$39.74M$44.15M$47.92M$45.03M$44.48M$49.43M$48.73M$40.45M$36.36M
    R&D$37.20M$33.53M$32.10M$30.82M$32.81M$36.44M$33.94M$33.26M$38.65M$38.06M$31.34M$27.15M
    SG&A$22.59M$15.23M$9.76M$8.92M$11.34M$11.48M$11.09M$11.22M$10.77M$10.66M$9.11M$9.21M
    Operating Income$-59,785,000$-48,769,000$-41,864,000$14.07M$-40,967,000$-42,530,000$-40,910,000$-32,878,000$-29,552,000$-42,255,000$-35,014,000$-25,626,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-3,723,000$-2,177,000$-1,680,000$-1,097,000$-1,239,000$-1,614,000$-1,813,000$-1,809,000$-2,071,000$-2,197,000$-2,236,000$-1,872,000
    Income Before Tax$-55,340,000$-45,513,000$-38,804,000$15.87M$-38,818,000$-39,842,000$-37,621,000$-29,113,000$-25,486,000$-37,874,000$-30,716,000$-22,240,000
    Income Tax Expense$1,000$1,000$-55,000$-10,000$35,000$34,000$49,000$54,000$65,000$40,000$47,000$23,000
    Net Income$-55,341,000$-45,514,000$-38,749,000$15.88M$-38,853,000$-39,876,000$-37,670,000$-29,167,000$-25,551,000$-37,914,000$-30,763,000$-22,263,000
    EBITDA$-58,638,000$-47,227,000$-40,005,000$15.33M$-39,432,000$-40,834,000$-38,814,000$-30,300,000$-26,925,000$-39,446,000$-32,335,000$-23,499,000
    EBIT$-59,063,000$-47,690,000$-40,484,000$14.78M$-40,057,000$-41,456,000$-39,434,000$-30,922,000$-27,557,000$-40,071,000$-32,952,000$-24,112,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TNGX

    News

    The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift

    Tango Therapeutics (TNGX) recently reported a wider net loss, launched a $400 million at-the-market equity offering, and made key leadership changes focused on commercialization. These moves indicate the company is preparing for later-stage development of vopimetostat, but also highlight potential shareholder dilution. Investors must weigh the potential of vopimetostat against funding risks and the stock's current high expectations.

    Simply Wall Street•8/20/26•
    Somewhat-Bearish

    Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX

    Trv Gp Vi LLC has acquired a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX), purchasing 194,174 shares valued at approximately $6.07 billion, making it their 4th largest position. The article highlights other institutional investments, insider selling, and current analyst ratings, which show a consensus "Moderate Buy" with an average price target of $43.46 despite a recent earnings miss. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer.

    MarketBeat•8/19/26•
    Somewhat-Bullish

    Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX

    Trv Gp Iv LLC has significantly invested in Tango Therapeutics, Inc. (NASDAQ:TNGX) by acquiring over 6.37 million shares, making it their second-largest holding. This investment, valued at approximately $120 billion, represents about 4.41% of Tango Therapeutics. Despite the company missing its recent quarterly EPS estimates, analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $43.46.

    MarketBeat•8/19/26•
    Somewhat-Bullish

    TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66

    H.C. Wainwright has increased its target price for Tango Therapeutics, Inc. (TNGX.O) from $66 to $68. This update reflects a positive adjustment in the firm's outlook for the biotechnology company. The news was reported by Reuters.

    Bitget•8/19/26•
    Bullish

    The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift

    Tango Therapeutics recently announced a wider net loss, a $400 million at-the-market equity offering, and leadership changes aimed at bolstering its commercialization efforts. These strategic moves suggest the company is preparing vopimetostat for late-stage development and commercial launch, though they also highlight potential shareholder dilution. The stock's current valuation already reflects high expectations despite the company's distant profitability.

    Simply Wall Street•8/19/26•
    Somewhat-Bearish

    Frequently Asked Questions About TNGX

    Does TNGX pay dividends?
    Tango Therapeutics Inc (TNGX) does not currently pay a regular dividend.
    What is TNGX's market cap?
    Tango Therapeutics Inc (TNGX) has a market capitalization of $3.85B with a current stock price of $22.84.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In